Vardenafil Dihydrochloride (Levitra)

A piperazine derivative, PHOSPHODIESTERASE 5 INHIBITOR and VASODILATOR AGENT that is used as a UROLOGICAL AGENT in the treatment of ERECTILE DYSFUNCTION.

Also Known As:

Levitra; 1-(((3-(3,4-dihydro-5-methyl)-4-oxo-7-propylimidazo(5,1-f)-as-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethylpiperazine; Vardenafil; Vardenafil Hydrochloride; Vardenafil Hydrochloride Anhydrous; Vardenafil Hydrochloride Trihydrate; Anhydrous, Vardenafil Hydrochloride; Dihydrochloride, Vardenafil; Hydrochloride Anhydrous, Vardenafil; Hydrochloride Trihydrate, Vardenafil; Hydrochloride, Vardenafil; Trihydrate, Vardenafil Hydrochloride

Networked: 543 relevant articles (95 outcomes, 134 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - Vardenafil Dihydrochloride: 543
  - Piperazines: 26
    - Vardenafil Dihydrochloride: 543

Experts

1.	Montorsi, Francesco: 17 articles (06/2008 - 05/2004)
2.	Vardenafil Study Group: 15 articles (04/2008 - 04/2003)
3.	Sandner, Peter: 11 articles (02/2017 - 12/2006)
4.	Porst, Hartmut: 10 articles (07/2008 - 09/2003)
5.	Maggi, Mario: 9 articles (01/2014 - 03/2007)
6.	Hellstrom, Wayne J G: 9 articles (02/2013 - 11/2002)
7.	Eardley, Ian: 9 articles (09/2011 - 11/2004)
8.	Kloner, Robert A: 9 articles (05/2007 - 04/2004)
9.	Beneke, Manfred: 8 articles (10/2011 - 07/2004)
10.	Ulbrich, Ernst: 8 articles (10/2011 - 07/2004)

Related Diseases

1.	Erectile Dysfunction 01/01/2006 - "Vardenafil was well tolerated and highly efficacious in men with erectile dysfunction and untreated mild major depression. " 01/01/2012 - "The efficacy of on-demand vardenafil ODT 10 mg was established in the POTENT I and II studies, which were 6-week, randomized, double-blind, multinational trials in men with erectile dysfunction of at least 6 months duration. " 06/01/2005 - "In this difficult to treat population of men with erectile dysfunction subsequent to NS-RRP on demand treatment with vardenafil during a 3-month period significantly improved key aspects of the sexual experience important to patient quality of life." 01/01/2002 - "In a large, placebo-controlled trial in patients with mild to severe erectile dysfunction (ED), vardenafil 5, 10 or 20mg taken as needed over a 12-week period significantly improved the scores in questions 3 and 4 of the International Index of Erectile Function (IIEF). " 04/01/2008 - "Vardenafil significantly improved ejaculation and self-confidence in men with erectile dysfunction due to SCI."
2.	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 01/01/2009 - "Stief, Hartmut Porst, Dieter Neuser, et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. " 06/01/2008 - "A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia." 07/01/2008 - "Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia." 09/01/2011 - "Placebo-controlled trials of tadalafil and vardenafil showed improvement of LUTS secondary to benign prostatic hyperplasia (BPH), but none of the studies showed a significant effect on urodynamic measures. " 09/01/2008 - "In patients on the doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia a single 10 mg dose of vardenafil had no symptomatic hemodynamic effects."
3.	Lower Urinary Tract Symptoms 10/01/2008 - "Should vardenafil be used for the treatment of lower urinary tract symptoms associated with BPH?" 01/01/2009 - "Stief, Hartmut Porst, Dieter Neuser, et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. " 06/01/2008 - "A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia." 07/01/2008 - "Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia." 03/01/2007 - "Overall, these results demonstrate that PDE5 regulates bladder smooth muscle tone, strongly limiting the nitric oxide/cGMP signaling, and that vardenafil, by blocking PDE5, may be a possible therapeutic option for bladder dysfunction by ameliorating irritative lower urinary tract symptoms."
4.	Hypertension (High Blood Pressure) 10/01/2008 - "Across all trials, vardenafil showed good efficacy for the treatment of ED in patients with diabetes, hypertension and dyslipidaemia. " 10/01/2008 - "The evidence presented in this review suggests that vardenafil is efficacious and well tolerated in patients with ED and diabetes, hypertension and/or dyslipidaemia and can be recommended as first-line treatment for ED in patients with these conditions." 10/01/2008 - "Relevant articles were identified through a PubMed search of clinical trials and postmarketing surveillance studies of vardenafil in patients with ED including those with diabetes, hypertension and dyslipidaemia. " 10/01/2007 - "Eight clinical trials were included (n = 2427 patients) consisting of 839 patients (35%) with a self-reported diagnosis of hypertension (HTN): 498 in the vardenafil and 341 in the placebo groups. " 10/01/2008 - "The concomitant use of medication to treat hypertension or dyslipidaemia was not associated with an increase in adverse events following vardenafil treatment. "
5.	Diabetes Mellitus 01/01/2002 - "A 12-week trial in 452 men with ED associated with diabetes mellitus demonstrated that treatment with vardenafil 20mg compared with placebo significantly improved IIEF erectile function domain scores and the rate of positive responders to the erectile improvement GAQ. " 08/01/2006 - "The efficacy of vardenafil has been demonstrated in a broad range of ED populations, but has not yet been assessed in Japanese patients with diabetes mellitus (DM), although DM is frequently associated with difficult-to-treat ED. " 01/01/2017 - "We report that vardenafil successfully prevented the development of diabetes mellitus-associated HFpEF. " 01/01/2004 - "Vardenafil improved erectile function in men with ED associated with diabetes mellitus or ED following unilateral or bilateral nerve-sparing radical retropubic prostatectomy in two randomised, double-blind, multicentre, fixed-dose, 3-month studies. " 01/01/2003 - "Vardenafil improved erectile function in men with ED associated with diabetes mellitus or ED following unilateral or bilateral nerve-sparing radical retropubic prostatectomy in two randomised, double-blind, multicentre, fixed-dose, 3-month studies. "

Related Drugs and Biologics

1.	Sildenafil Citrate (Viagra)
2.	Tadalafil (Cialis)
3.	Phosphodiesterase 5 Inhibitors
4.	Type 5 Cyclic Nucleotide Phosphodiesterases
5.	Vardenafil Dihydrochloride (Levitra)
6.	Tamsulosin (Flomax)
7.	Phosphoric Diester Hydrolases (Phosphodiesterases)
8.	avanafil
9.	Bosentan (Tracleer)
10.	Doxazosin (Cardura)

Related Therapies and Procedures

1.	Therapeutics
2.	Prostatectomy (Retropubic Prostatectomy)
3.	Drug Therapy (Chemotherapy)
4.	Transplantation
5.	Intranasal Administration